Success Metrics

Clinical Success Rate
100.0%

Based on 17 completed trials

Completion Rate
100%(17/17)
Active Trials
0(0%)
Results Posted
94%(16 trials)

Phase Distribution

Ph phase_2
2
12%
Ph phase_3
15
88%

Phase Distribution

0

Early Stage

2

Mid Stage

15

Late Stage

Phase Distribution17 total trials
Phase 2Efficacy & side effects
2(11.8%)
Phase 3Large-scale testing
15(88.2%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

17 of 17 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

17

all time

Status Distribution
Completed(17)

Detailed Status

Completed17

Development Timeline

Analytics

Development Status

Total Trials
17
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 22 (11.8%)
Phase 315 (88.2%)

Trials by Status

completed17100%

Recent Activity

Clinical Trials (17)

Showing 17 of 17 trials
NCT03621670Phase 3

Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants

Completed
NCT03893448Phase 3

Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)

Completed
NCT03620162Phase 3

A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)

Completed
NCT03207750Phase 3

This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine

Completed
NCT00814710Phase 3

Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 10 Weeks of Age

Completed
NCT02096263Phase 3

Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants

Completed
NCT01309646Phase 3

Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib Vaccine

Completed
NCT00547248Phase 3

Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previously Primed With the Same Vaccines

Completed
NCT00344318Phase 3

Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine

Completed
NCT00326118Phase 3

Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC & to Evaluate Persistence up to 5 Years.

Completed
NCT00169442Phase 3

Immune Memory of DTPw-HBV/Hib Vaccine Following Primary Vaccination, Immuno & Reacto of a Booster Dose Given in Infants

Completed
NCT00291343Phase 3

Immune Response & Safety of GSK Biologicals' Mencevax™ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 Study

Completed
NCT00696423Phase 3

Immunogenicity and Safety of GSK Biologicals' Infanrix/Hib in Children

Completed
NCT00412854Phase 3

Study to Assess Safety & Immunogenicity of GSK Biologicals' DTPa/Hib Vaccine vs Separate Administration of DTPa and Hib.

Completed
NCT00317109Phase 3

Study to Asses DTPw-HBV/Hib at 15-18 Months (m) and Mencevax™ ACW at 24 to 30 m in Primed Subjects

Completed
NCT00323622Phase 2

Long-Term Follow-up of Children for a 2-Year Period to Confirm the Safety and Immunogenicity of GSK 257049 Vaccine

Completed
NCT01061541Phase 2

Immunogenicity, Safety & Reactogenicity of GSK Vaccine Tritanrix™-HepB/Hib2.5 Compared to GSK Vaccine Tritanrix™-HepB/Hiberix™

Completed

All 17 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
17